Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Free Report) - Stock analysts at HC Wainwright boosted their Q1 2027 earnings per share estimates for Inhibikase Therapeutics in a note issued to investors on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.12) per share for the quarter, up from their previous estimate of ($0.13). HC Wainwright has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for Inhibikase Therapeutics' current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Inhibikase Therapeutics' Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.42) EPS.
Other equities analysts also recently issued reports about the stock. Chardan Capital restated a "neutral" rating and set a $1.50 target price on shares of Inhibikase Therapeutics in a report on Thursday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inhibikase Therapeutics in a report on Thursday, October 15th. Finally, Wall Street Zen upgraded shares of Inhibikase Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday. Three analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Inhibikase Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $4.75.
View Our Latest Analysis on Inhibikase Therapeutics
Inhibikase Therapeutics Stock Performance
Shares of NASDAQ IKT opened at $1.52 on Monday. The stock has a market cap of $213.21 million, a price-to-earnings ratio of -3.80 and a beta of 0.94. Inhibikase Therapeutics has a 52 week low of $1.40 and a 52 week high of $2.61. The company's 50-day moving average price is $1.90 and its 200 day moving average price is $1.93.
Inhibikase Therapeutics (NASDAQ:IKT - Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01.
Hedge Funds Weigh In On Inhibikase Therapeutics
Several hedge funds have recently bought and sold shares of IKT. Abel Hall LLC boosted its stake in shares of Inhibikase Therapeutics by 15.0% during the third quarter. Abel Hall LLC now owns 53,311 shares of the company's stock valued at $110,000 after acquiring an additional 6,959 shares during the last quarter. Spark Investment Management LLC purchased a new position in Inhibikase Therapeutics in the 2nd quarter valued at about $31,000. Renaissance Technologies LLC acquired a new stake in shares of Inhibikase Therapeutics during the 1st quarter worth about $28,000. Seven Fleet Capital Management LP boosted its stake in shares of Inhibikase Therapeutics by 6.5% during the 2nd quarter. Seven Fleet Capital Management LP now owns 346,900 shares of the company's stock worth $704,000 after purchasing an additional 21,300 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Inhibikase Therapeutics during the first quarter worth about $48,000. Hedge funds and other institutional investors own 3.81% of the company's stock.
About Inhibikase Therapeutics
(
Get Free Report)
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Parkinson's disease and other neurodegenerative disorders. The company's research centers on small-molecule inhibitors of Abelson tyrosine kinase, or c-Abl, a protein it is investigating for its role in neurodegeneration. Its pipeline has included IKT-148009, an oral c-Abl inhibitor being developed for Parkinson's disease. Inhibikase is based in Atlanta, Georgia, and conducts research and development in the pharmaceutical biotechnology sector.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inhibikase Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.
While Inhibikase Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.